Economic advice, method- and data-based

In Switzerland significant demand for H₂ has yet to emerge. High electricity and operating costs challenge the economic viability of projects; existing electrolysis capacities remain unused. The current draft of the gas supply act (GasVG) offers little encouragement: renewable gases play only a marginal role. Unlike for renewable electricity, grid feed-in charges remain possible – and an additional cost driver. There is also no possibility to introduce blending quotas. There remains little incentive to accelerate investment or stimulate demand in the future. For the use of renewable gases – and new technologies – their price and the cost of their utilisation are decisive factors. Resilient planning therefore requires an economic approach: relative costs and price elasticities determine when and where additional demand may arise. These insights form the basis for aligning infrastructure, grid development plans and import capacities in a timely manner. The Barometer is published by VSG in collaboration with E-Bridge Consulting and Polynomics. It can be subscribed to at https://gazenergie.ch/de/h2-barometer.

Arbeiten Sie gerne mit Daten, haben sehr gute Kenntnisse in R und sind bereit, sich in neue, technische Aufgabenfelder einzuarbeiten, dann freuen wir uns auf Ihre Bewerbung.

Duchenne muscular dystrophy (DMD) is a degenerative muscle disease that is inherited via the X-chromosome. The gradual degeneration of the muscles leads to complete paralysis of the extremities and thus to the loss of the ability to walk, to a high level of care dependency and finally to a premature death. There are no licensed therapies in Austria at present that can stop the degenerative progress of the disease. What are the social costs of DMD in Austria? For the first time, we deter-mined the direct, indirect and intangible costs for each of the four stages of the disease. Wherever possible, we referred to Austrian information on prices and quantities and alternatively used information from international literature or expert estimates. The social costs of DMD totalled EUR 30 million in 2023, which corre-sponds to EUR 131,000 per patient. Of this amount, 78% (EUR 23.5 mil-lion) were indirect costs arising from productivity losses among patients and their relatives (informal caregiving) and from premature death. The indirect costs were significantly higher than the direct costs in all four stages of the disease. The majority of the social costs (48%) were incurred during the last stages of the disease in which the patients have already lost their ability to walk. At last, we estimated the lifetime costs of one patient with an average disease progression to be EUR 4.7 million, accompanied by a loss of ap-proximately 60 quality-adjusted life years (QALYs).